Although overall BMP9 and BMP10 levels did not differ between PAH patients and controls, a subset of PAH patients had markedly reduced plasma levels of BMP9 and BMP10 in the absence of GDF2 mutations. This evidence concerns the gene GDF2 and pulmonary arterial hypertension.